Letter Ahead of print
PubMed: 42573556 DOI: 10.1002/ajh.70470
Real-World Outcomes of Venetoclax-Based Therapy in Treatment-Naïve and Relapsed/Refractory CLL/SLL: Interim Results From the Prospective REVEAL Study.
Am J Hematol
Authors: Yair Herishanu, Neta Goldschmidt, Gilad Itchaki, Liron Hofstetter, Osnat Bairey, Yotam Bronstein, Itai Levi, Ariel Aviv, Riva Fineman, Najib Dally, Tamar Tadmor, Aaron Ronson, Uri Abadi, Lev Shvidel, Galia Stemer, Chen Glait Santar, Tara Weinstein, Alex Bleterman, Brit Vidmayer, Ohad Benjamini
Affiliations
- Department of Hematology, Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel.
- Gray Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel.
- Department of Hematology, Hadassah Hebrew University Medical Center, Jerusalem, Israel.
- Hematology Institute, Meir Medical Center, Kfar Saba, Israel.
- Institute of Hematology, Rabin Medical Center, Beilinson Hospital, Petah Tikva, Israel.
- Hematology Institute, Soroka Medical Center, Beer-Sheba, Israel.
- Department of Hematology, Ha'emek Medical Center, Afula, Israel.
- Department of Hematology, Rambam Health Care Campus, Haifa, Israel.
- Institute of Hematology and Blood Bank, Ziv Medical Center, Safed, Israel.
- Azrieli Faculty of Medicine, Bar Ilan University, Safed, Israel.
- Hematology Unit, Bnai Zion Medical Center, Haifa, Israel.
- The Ruth and Bruce Rappaport Faculty of Medicine, Technion, Haifa, Israel.
- Department of Hematology, Shaare-Zedek Medical Center, Affiliated With the Hebrew University Medical School, Jerusalem, Israel.
- Department of Hematology, Kaplan Medical Center, Rehovot, Israel.
- Hebrew University of Jerusalem, Jerusalem, Israel.
- Institute of Hematology, Galilee Medical Center, Nahariya, Israel.
- AbbVie Inc. Hod-Hasharon, Israel.
- Hematology Division, Chaim Sheba Medical Center, Ramat Gan, Israel.
MeSH
Hematology, Therapeutics